An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis

Archives of Dermatology

Volumn 139, Issue 6, 2003, Pages 719-727

  Lebwohl, Mark ^a   Christophers, Enno ^b   Langley, Richard ^c   Ortonne, Jean P ^d   Roberts, Janet ^e   Griffiths, Christopher E M ^f  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KIEL   (Germany)

^c DALHOUSIE UNIVERSITY   (Canada)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^e Northwest Cutaneous Research Specialists   (United States)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; CD4 ANTIGEN;

ACCIDENT; ADULT; ARTICLE; ASTHENIA; CELL COUNT; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INJURY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCORING SYSTEM; T LYMPHOCYTE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CANADA; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; PSORIASIS; RECOMBINANT FUSION PROTEINS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES;

EID: 0038385972     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.139.6.719     Document Type: Article

References (46)

1. Christophers E. Psoriasis: epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26:314-320.
2. Fortune DG, Main CJ, O'Sullivan TM, Gdffiths CEM. Assessing illness-related stress in psoriasis: the psychometric properties of the psoriasis life stress inventory. J Psychosom Res. 1997;42:467-475.
3. Linden KG, Weinstein GD. Psoriasis: current perspectives with an emphasis on treatment. Am J Med. 1999;107:595-605.
4. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life. Arch Dermatol. 2001;137:280-284.
5. Fortune DG, Main CJ, O'Sullivan TM, Griffiths CE. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol. 1997;137:755-760.
6. Lebwohl M, Ali S. Treatment of psoriasis, I: topical therapy and phototherapy. J Am Acad Dermatol. 2001;45:487-498.
7. Lebwohl M, Ali S. Treatment of psoriasis, II: systemic therapies. J Am Acad Dermatol. 2001;45:649-661.
8. Koo J, Lebwohl M. Duration of remission in psoriasis therapies. J Am Acad Dermatol. 1999;41:51-59.
9. Ashcroft DM, Li Wan Po A, Griffiths CEM. Therapeutic strategies for psoriasis. J Clin Pharm Ther. 2000;25:1-10.
10. Boerbooms AM, Kerstens PJ, van Loenhout JW, Mulder J, van de Putte LB. Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum. 1995;24:411-421.
11. Robert C, Kupper TS. Inflammatory skin diseases, T cells and immune surveillance. N Engl J Med. 1999;341:1817-1828.
12. Delves PJ, Roitt IM. The immune system. N Engl J Med. 2000;343:37-49.
13. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 2002;46:1-23.
14. Ellis CN, Fradin MS, Messana JM, et al. Cyclosporine for plaque-type psoriasis: results of a multidose, double-blind trial. N Engl J Med. 1991;324:277-284.
15. Bos JD, De Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today. 1999;20:40-46.
16. Gordon KB, West DP. Biologic therapy in dermatology. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy. Philadelphia, Pa: WB Saunders; 2001:928-942.
17. Miller GT, Hochman PS, Meier W, et al. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med. 1993;178:211-222.
18. Majeau GR, Meier W, Jimmo B, Kioussis D, Hochman PS. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses: structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol. 1994;152:2753-2767.
19. Meier W, Gill A, Rogge M, et al. Immunomodulation by LFA3TIP, an LFA-3/IgG1 fusion protein: cell line dependent glycosylation effects on pharmacokinetic and pharmacodynamic markers. Ther Immunol. 1995;2:159-171.
20. Sanders ME, Makgoba MW, Sharrow SO, et al. Human memory T lymphocytes express increased levels ofthree cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-γ production. J Immunol. 1988;140:1401-1407.
21. Majeau GR, Whitty A, Yim K, Meier W, Hochman PS. Low affinity binding of an LFA-3/IgG1 fusion protein to CD2+ T cells is independent of cell activation. Cell Adhes Commun. 1999;7:267-279.
22. + lymphocytes [abstract 518]. J Invest Dermatol. 1999;112:609.
23. Ellis CN, Krueger GG, for the Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory-effector T lymphocytes. N Engl J Med. 2001;345:248-255.
24. Bos JD, Hagenaars C, Das PK, Krieg SR, Voorn WJ, Kapsenberg ML. Predominance of "memory" T cells (CD4+, CDw29+) over "naïve" T cells (CD4+, CD45R+) in both normal and diseased human skin. Arch Dermatol Res. 1989;281:24-30.
25. Morganroth GS, Chan LS, Weinstein GD, Voorhees JJ, Cooper KD. Proliferating cells in psoriatic dermis are comprised primarily of T cells, endothelial cells and factor XIIIa+ perivascular dendritic cells. J Invest Dermatol. 1991;96:333-340.
26. Fuhlbrigge RC, Kieffer JD, Armerding D, Kupper TS. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature. 1997;389:978-981.
27. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type I cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol. 1999;113:752-759.
28. Friedrich M, Krammig S, Henze M, Docke WD, Sterry W, Asadullah K. Flow cytometric characterisation of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype. Arch Dermatol Res. 2000;292:519-521.
29. TenHoor C, Vaishnaw A. Tolerability, biological activity, and pharmacokinetics of alefacept administered as an intravenous infusion, intramuscular injection, and intravenous bolus injection [abstract P24-56]. J Eur Acad Dermatol Venereol. 2001;15(suppl 2):251.
30. Fredriksson T, Petterson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica. 1978;157:238-244.
31. Finlay AY, Salek MS, Haney J. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology. In press.
32. CDSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms. 5th ed. Rockville, Md: Food and Drug Administration; 1995. Publication FDA/CDER-95/24.
33. Krueger GG, Papp KA, Stough DB, et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and safety of two courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2002;47:821-833.
34. Ellis CN, Fradin MS, Hamilton TA, Voorhees JJ. Duration of remission during maintenance cyclosporine therapy for psoriasis: relationship to maintenance dose and degree of improvement during initial therapy. Arch Dermatol. 1995;131:791-795.
35. Cacoub P, Artru L, Canesi M, Koeger AC, Camus JP. Life-threatening psoriasis relapse on withdrawal of cyclosporin. Lancet. 1988;2:219-220.
36. De Silva BD, Benton EC, Tidman MJ. Generalized pustular psoriasis following withdrawal of oral cyclosporin treatment for palmo-plantar pustulosis. Clin Exp Dermatol. 1999;24:10-13.
37. Gottlieb A, Casale T, Goffe B, et al. Impact of a 12-week course of alefacept therapy on primary and secondary immune responses in psoriasis patients [abstract P24-21]. J Eur Acad Dermatol Venereol. 2001;15(suppl 2):242.
38. Von Andrian UH, Mackay CR. T-cell function and migration: two sides of the same coin. N Engl J Med. 2000;343:1020-1034.
39. Reinhardt RL, Khoruts A, Merica R, Zell T, Jenkins MK. Visualizing the generation of memory CD4 T cells in the whole body. Nature. 2001;410:101-105.
40. Baars PA, Ribeiro Do Couto LM, et al. Cytolytic mechanisms and expression of activation-regulating receptors on effector-type CD8+CD45RA+CD27-human T cells. J Immunol. 2000;165:1910-1917.
41. Hamann D, Baars PA, Rep MH, et al. Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med. 1997;186:1407-1418.
42. Hamann D, Kostense S, Wolthers KC, et al. Evidence that human CD8+CD45RA+CD27: cells are induced by antigen and evolve through extensive rounds of division. Int Immunol. 1999;11:1027-1033.
43. Michie CA, McLean A, Alcock C, Beverley PC. Lifespans of human lymphocyte subsets defined by CD45 isoforms. Nature. 1992;360:264-265.
44. McLean AR, Michie CA. In vivo estimates of division and death rates of human T lymphocytes. Proc Natl Acad Sci USA. 1995;92:3707-3711.
45. Hakim FT, Cepeda R, Kaimei S, et al. Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood. 1997;90:3789-3798.
46. Dumont-Girard F, Roux E, van Lier RA, et al. Reconstitution of the T-cell compartment after bone marrow transplantation: restoration of the repertoire by thymic immigrants. Blood. 1998;92:4464-4471.